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Background: Chronic lung disease continues to be a major complication in premature 
infants with severe respiratory distress syndrome (RDS). This is despite having advanced 
ventilatory care, prenatal corticosteroids, and postnatal surfactant therapies. The 
combined use of intratracheal corticosteroids and surfactant may not only recruit the 
lungs, but also alleviate pulmonary inflammation in severe RDS.
Methods: Fifteen newborn piglets received repeated pulmonary saline lavage to 
induce surfactant-depleted lungs, mimicking neonatal RDS. They were randomly 
divided into three groups: control group receiving no treatment; surfactant (Surf) group, 
treated with standard intratracheally instilled surfactant (100 mg/kg); and Budesonide 
plus surfactant (Bude + Surf) group, treated with intratracheally administered mixed 
suspension of budesonide (0.5 mg/kg) and surfactant (100 mg/kg). Blood samples were 
taken every 30 minutes for 4 hours. Lung tissue was examined after the experiment.
Results: Significantly better oxygenation with higher PaO2 and alveolar-arterial 
oxygen difference was noted in the Surf and Bude + Surf groups, compared with the 
control group (p < 0.05), but there were no significant differences between the Surf 
and Bude + Surf groups. Pulmonary histologic damage was also markedly alleviated in 
both the Surf and Bude + Surf groups, compared with the control group, and lung 
injury scores were significantly decreased in the Surf and Bude + Surf groups, com-
pared with the control group (p < 0.05).
Conclusions: Intratracheal instillation of surfactant or surfactant plus budesonide 
can improve oxygenation and pulmonary histologic outcome in neonatal surfactant-
depleted lungs. The additional use of budesonide does not disturb the function of 
the exogenous surfactant. Intratracheal administration of a corticosteroid com-
bined with surfactant may be an effective method for alleviating local pulmonary 
inflammation in severe RDS.
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1.  Introduction
Respiratory distress syndrome (RDS) is a common 
cause of severe respiratory failure in the neonatal 
intensive care unit, and remains a major cause of 
morbidity and mortality in premature infants.1−3 
The pathophysiology of RDS typically includes defi-
cient synthesis or release of endogenous surfactant 
in premature lungs. Pulmonary inflammation follow-
ing respiratory failure and ventilatory care plays 
an important role in the development of pulmonary 
fibrosis and chronic lung disease (CLD) in extremely 
premature infants.4
Exogenous surfactant supplementation has been 
used in preterm infants with RDS since the early 
1990s,2 and it has been proven to be a crucial thera-
peutic method for treating premature infants with 
RDS.2,5,6 Antenatal corticosteroid application has 
also been used and shown to be effective in stimu-
lating pulmonary maturation and fetal surfactant 
synthesis, thus causing significant reduction in the 
severity of RDS in premature infants.2,3,7,8 However, 
CLD continues to be a major complication in prema-
ture infants, despite recent advances in ventilatory 
care and the use of prenatal corticosteroids and 
postnatal surfactant.1,2,9
Postnatal systemic use of corticosteroids has been 
used with the aim of ameliorating the severity of CLD 
in premature infants with RDS.9−13 However, sys-
temic administration of corticosteroids to these 
neonates may be associated with significant short- 
and long-term adverse effects, and their use there-
fore remains controversial.5,14−18 In contrast, local 
intratracheal administration of corticosteroids may 
have the potential to prevent inflammatory insult to 
the lungs without the development of systemic side 
effects.4,15 However, there is no strong evidence 
demonstrating significant benefits associated with in-
haled corticosteroids in these premature infants.4,15 
Intratracheal instillation is an alternative method 
of corticosteroid administration. However, further 
research is needed to elucidate the short- and long-
term benefits and adverse effects associated with 
postnatal intratracheal corticosteroid use.4,15
Yeh et al9 reported that the combined use of an 
intratracheal corticosteroid (budesonide) and sur-
factant resulted in improved survival and a lower in-
cidence of CLD in extremely premature infants, with 
no clinically significant adverse effects. This combi-
nation of an intratracheally administered corticoste-
roid and surfactant may therefore represent a novel 
and promising means of improving the outcome of 
premature infants with severe RDS. However, future 
clinical application requires histopathologic evidence 
to determine if the additional use of intratracheal 
corticosteroid instillation and surfactant disturbs or 
improves the effects of standard surfactant therapy.
We hypothesized that intratracheal instillation 
of budesonide in addition to exogenous surfactant 
might suppress pulmonary inflammation without dis-
turbing the pulmonary recruitment effects of stand-
ard surfactant therapy in RDS. This study therefore 
investigated the pathophysiological effects of in-
tratracheal instillation of budesonide combined with 
the standard exogenous surfactant in a newborn 
piglet model with surfactant-depleted lungs.
2.  Materials and Methods
All animals were managed in accordance with the 
principles of laboratory animal care of the National 
Institutes of Health. In addition, all procedures were 
approved by the Institutional Animal Care and Use 
Committee of Taipei Veterans General Hospital.
2.1.  Animal preparation
Neonatal piglets (less than 2 weeks old) were an-
esthetized with inhaled isoflurane until they were 
calm. Then they were injected intramuscularly with 
atropine (0.1 mg/dose) and ketamine (10 mg/kg/
dose), prior to performing surgical procedures. All 
animals were placed in a supine position, with a 
subcutaneous injection of lidocaine hydrochloride 
(2%) for local anesthesia. After placing a 3.5-mm in-
side diameter Portex uncuffed tracheal tube (SIMS 
Portex Limited, Hythe, UK) via tracheotomy, con-
trolled mechanical ventilation was established using 
a volume-controlled ventilator (Model 683; Harvard 
Apparatus, Holliston, MA, USA). Tidal volume (Vt) was 
set at 10 mL/kg, and the respiratory rate was set at 
30 breaths/minutes. The other ventilator settings 
included I:E ratio of 1:1, positive end-expiratory 
pressure of 5 cmH2O, and fractional concentration 
of inspired oxygen (FiO2) of 1.0. These ventilator 
settings were kept constant throughout the exper-
iments. A 3.5-Fr umbilical vessel catheter (Argyle, 
Sherwood Medical Company, St. Louis, MO, USA) was 
placed in the right femoral vein for medication and 
anesthesia. After the induction of anesthesia, a so-
lution of 0.33% saline in 5% dextrose was infused at 
a rate of 5 mL/kg/h. Animals were paralyzed with 
intravenous pancuronium bromide (0.2 mg/kg), then 
sedated with midazolam (0.5 mg/kg). A continuous 
infusion of a combination of ketamine (5 mg/kg/h), 
midazolam (0.5 mg/kg/h), and pancuronium (0.2 mg/
kg/h) was maintained. Another 3.5-Fr umbilical ves-
sel catheter (Argyle, Sherwood Medical Company) 
was placed into the right femoral artery for con-
tinuous recording of arterial blood pressure and 
for blood sampling. Body temperature was main-
tained at 38−39ºC throughout the experiment with 
a servo-controlled heating blanket.19−21
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2.2.  Physiological monitoring
Electrocardiography, mean arterial blood pressure, 
oxygen saturation detected by pulse oximetry (SpO2), 
and anal temperature were continuously monitored 
throughout the experiment using an HP M1205A 
Omni Care Model 24/24C (Hewlett-Packard, Palo 
Alto, CA, USA). Respiratory flow was measured with 
a Fleisch No. 3 heated capillary-tube pneumotacho-
graph (Phipps & Bird, Richmond, VA, USA) coupled 
to a differential pressure transducer (MP-45-16; 
Validyne, Northridge, CA, USA). All pressure trans-
ducers were calibrated using a water or mercury 
manometer. All signals for respiratory flow and air-
way pressure were recorded using a data acquisi-
tion system (PowerLab 16/30, ADInstruments Pty 
Ltd., Bella Vista, Australia). The flow signal was in-
tegrated to give Vt readings, and compliance of the 
respiratory system (Crs) was measured on a breath-
by-breath basis using an on-line computer system 
equipped with an analog/digital converter (DA100C; 
BIOPAC Systems, Inc., Goleta, CA, USA) and appro-
priate software (Chart & Scope, ADInstruments Pty 
Ltd.). Arterial blood samples were taken for blood 
gas analysis (STAT3; Nova Biomedical Corpo ration, 
Waltham, MA, USA).
2.3.  Induction of acute lung injury
After obtaining baseline measurements in all ani-
mals on conventional mechanical ventilation, lung-
injury mimicking neonatal surfactant-deficient RDS 
was induced by repeatedly lavaging the lungs with 
10 mL/kg of warm normal saline solution until in-
jury entry criteria were achieved: PaO2 < 100 mmHg 
with a > 2/3 decrease in Crs maintained for more 
than 15 minutes.22−24
2.4.  Experimental protocols
A total of 15 neonatal piglets were randomly and 
evenly divided into the three study groups: (1) 
control group, which received no treatment; (2) 
surfactant (Surf) group, which was treated with in-
tratracheal instillation of standard exogenous sur-
factant (100 mg/kg, Survanta; Abbott Laboratories, 
Abbott Park, IL, USA) divided into four equal aliq-
uots and instilled in four positions; and (3) Bude-
sonide plus surfactant (Bude + Surf) group, which was 
treated with intratracheal instillation of a mixed 
suspension of budesonide (0.5 mg/kg, Pulmicort neb-
ulizing suspension; AstraZeneca, Lund, Sweden) 
and standard exogenous surfactant (100 mg/kg) di-
vided into four equal aliquots and instilled in four 
positions.
Arterial blood samples were checked every 30 min-
utes until the end of the experiments (4 hours) or the 
death of the animal before 4 hours. Cardio pulmonary 
profiles were also recorded every 30 minutes.
The animals were euthanized at the end of the 
experiments with a high dose of 15% potassium chlo-
ride. With the positive end expiratory pressure kept 
at 5 cmH2O, the chest was opened and the lungs were 
inspected to assess gross morphology. Two blocks of 
the right lung (non-dependent site of the middle 
lobe and dependent site at the superior segment of 
the lower lobe, around 1 cm3) were obtained and 
fixed by immersion in 10% formaldehyde solution for 
more than 24 hours. Tissue specimens were embed-
ded in paraffin and cut into sections, which were 
subsequently stained with hematoxylin and eosin. 
Sections were examined by light microscopy in a 
blinded fashion (Olympus AX-80; Yuanyu Industry Co., 
Ltd., Taipei, Taiwan). His tology was scored using a 
quantitative scoring system by an investigator blinded 
to the study group. The injury variables scored were: 
alveolar and interstitial inflammation, alveolar and 
interstitial hemorrhage, atelectasis, and necrosis. 
The severity of injury was graded according to the 
following scale: no injury (0); injury to 25% of the 
field (1); injury to 50% of the field (2); injury to 
75% of the field (3); and diffuse injury (4).19,25,26
2.5.  Statistical analysis
Values are presented as mean ± standard error of 
the mean for parametric data and median (range) for 
nonparametric data. Data analysis was performed 
using SigmaStat 3.1 (Systat Software, Inc., Point 
Richmond, CA, USA). Paired t tests were performed 
to determine statistical differences within groups in 
terms of pre- and post-injury cardiopulmonary data. 
One-way analysis of variance or Kruskal-Wallis tests 
were used to compare data among different groups, 
as appropriate. Two-way repeated measures analy-
sis of variance was used to compare serial cardiop-
ulmonary data in different groups over time. Post 
hoc analysis was performed using the Student-
Newman-Keuls test for all pairwise comparisons. 
Statistical significance was defined as p < 0.05.
3.  Results
There were no significant differences in age or 
weight of the experimental piglets among the three 
study groups (Control: 1.5 ± 0.1 kg and 8 ± 1 days old; 
Surf group: 1.7 ± 0.1 kg and 10 ± 1 days old; Bude + 
Surf group: 1.7 ± 0.1 kg and 9 ± 1 days old). There 
were no significant differences among the three study 
groups in terms of pre- or post-injury data (Table 1). 
Regarding the pre- and post-injury data within the 
same group, there were significant decreases in ar-
terial PaO2, pH, and Crs, and a significant increase 
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in PaCO2. Mean arterial blood pressure and heart 
rate showed no significant changes (Table 1).
All animals in the Surf and Bude + Surf groups 
survived throughout the experiments, but one ani-
mal in the control group died at 215 minutes, as a 
result of severe pulmonary hemorrhage.
Gas exchange in the experimental piglets is shown 
in Figure 1. A significantly higher PaO2 and lower 
alveolar−arterial oxygen difference were noted dur-
ing the experimental period in both the Surf and 
Bude + Surf groups, compared with the control group, 
using 2-way repeated measures analysis of variance 
for comparison (p < 0.05), but there was no significant 
difference between the Surf and Bude + Surf groups 
(Figure 1A and 1B). There was a tendency towards 
a more stable pH and lower PaCO2 in the Surf and 
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Figure 1 Changes in arterial blood gases in control (n = 5), surfactant (Surf, n = 5), and Budesonide plus surfactant 
(Bude + Surf, n = 5) groups during the experimental 4-hour period. Values are mean ± standard error of the mean. 
*p < 0.05 versus the control group over 4 hours by two-way repeated measures analysis of variance.
Table 1  Effects of repeated saline lavage injury on cardiopulmonary parameters in control, surfactant (Surf), and 
Budesonide plus surfactant (Bude + Surf) groups*
Time Group (n) pH
 PaCO2 PaO2 Crs Heart rate Mean blood
   (mmHg) (mmHg) (mL/cmH2O/kg) (beats/min) pressure (mmHg)
Pre-injury Control (6) 7.43 ± 0.04 39 ± 4 386 ± 45 1.07 ± 0.17 187 ± 10 82 ± 4
 Surf (5) 7.40 ± 0.02 36 ± 2 358 ± 21 0.95 ± 0.16 192 ± 24 78 ± 4
 Bude + Surf (5) 7.43 ± 0.04 38 ± 4 404 ± 25 1.01 ± 0.10 214 ± 20 79 ± 4
Post-injury Control (6) 7.28 ± 0.03† 52 ± 4† 78 ± 4† 0.51 ± 0.05† 170 ± 11 85 ± 4
 Surf (5) 7.31 ± 0.02† 49 ± 4† 89 ± 4† 0.59 ± 0.06† 168 ± 18 85 ± 9
 Bude + Surf (5) 7.31 ± 0.03† 47 ± 3† 95 ± 4 0.64 ± 0.05† 200 ± 25 84 ± 8
*Data are expressed as mean ± standard error of the mean; †p < 0.05 versus the corresponding pre-injury data for the same group.
Crs = compliance of the respiratory system.
Bude + Surf groups than in the control group, but the 
difference was not significant (Figure 1C and 1D).
The positive inspiratory pressure, Crs, heart rate 
and mean arterial blood pressure were not signifi-
cantly different among the three study groups over 
the 4-hour experiments (Figure 2).
The gross appearance of the lungs in the Control 
group showed multiple focal atelectasis, hemor-
rhage, and minimal pleural effusions in the pleural 
cavity; these were much less common in the two 
treatment groups. Representative photomicrographs 
of the histologic findings (non-dependent site of each 
group) are demonstrated in Figure 3. As shown, 
marked alveolar damage with severe inflamma-
tion, hemorrhage, atelectasis, edema, and necrosis 
were noted in the control group; this damage was 
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markedly alleviated in the Surf and Bude + Surf 
groups. The total lung injury score for the control 
group was significantly higher than that for the other 
two groups in both dependent and non-dependent 
sites (Table 2), but there was no significant differ-
ence between the Surf and Bude + Surf groups.
4.  Discussion
The results of this study demonstrated that the treat-
ment of neonatal surfactant-depleted piglets with 
exogenous surfactant alone, or combination ther-
apy with intratracheally administered budesonide 
and surfactant both resulted in better oxygenation 
and histopathologic protection compared with no 
treatment. No significant pathophysiological differ-
ences were demonstrated between the two treat-
ment groups during the hyper-acute stage (first 4 
hours) of lung injury. Thus the use of intratracheal 
budesonide did not disturb the function of exogenous 
surfactant, but further investigations are needed to 
determine if greater benefit could be obtained.
RDS and CLD are still common causes of morbidity 
and mortality in the neonatal intensive care unit. 
Investigation into the best way to reduce disease 
severity without increasing adverse effects is the key 
to future care. An effective therapy for treating 
Control Surf Bude + surf
100 μm
Figure 3 Representative pulmonary histologic images from the non-dependent sites of the three study groups 
(stained with hematoxylin & eosin). Significant hemorrhage, atelectasis, and inflammatory infiltrations occurred in 
the control group, and these were much less evident in the other two groups (original magnification, 100×).
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Figure 2 Changes in cardiopulmonary profiles in control (n = 5), surfactant (Surf, n = 5), and Budesonide plus surfactant 
(Bude + Surf, n = 5) groups during the experimental 4-hour period. Values are mean ± standard error of the mean. There 
were no significant differences among different groups throughout the experiments by two-way repeated measures anal-
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premature lungs with RDS, as well as the associated 
pulmonary inflammation, needs to effectively re-
cruit the lungs and reduce the inflammatory reaction. 
Combination therapy using intratracheal instillation 
of standard exogenous surfactant and corticoste-
roids might not only recruit the lungs, but also 
alleviate the pulmonary inflammation, and finally 
improve the outcome in premature infants with 
severe RDS. The present study demonstrated that 
the direct intratracheal instillation of a suspension 
mixture of these two drugs, budesonide and sur-
factant, provided a feasible method for treating 
surfactant-deficient lungs, and that the additional 
use of budesonide did not reduce the effects of the 
surfactant. These results were compatible with 
those of Yeh et al9 in premature infants.
The therapeutic role and different ways of 
administering corticosteroids for the treatment and 
prevention of CLD in premature infants have been 
investigated for decades,17,27−30 but the results are 
still inconclusive. The balance between the benefits 
and adverse effects of corticosteroids remain a major 
concern. The major adverse effects of corticosteroids 
in premature infants include hyperglycemia, sepsis, 
hypertension, hypertrophic obstructive cardiomyo-
pathy, gastrointestinal hemorrhage or perforation, 
growth failure, and hypothalamic-pituitary-adrenal 
axis suppression.4 Local use of corticosteroids has 
the potential to retain their anti-inflammatory ef-
fects without increasing the risk of systemic adverse 
effects. Nebulized inhalation and direct intratra-
cheal instillation are both possible techniques for 
the local administration of corticosteroids into the 
lungs. Inhaled corticosteroids have been tried,4,15,31 
but failed to demonstrate effectiveness in reduc-
ing the incidence of CLD.4,15 The problem of parti-
cle deposition into the small airways and deep 
alveoli in tiny premature infants may influence the 
therapeutic effects of nebulization. How ever, in-
tratracheal instillation provides a direct means of 
delivering drugs to the deep airways and bypass 
systemic circulation, and has been experimentally 
and successfully tried in some animal models of 
different types of acute lung injury using saline, 
surfactant, or perfluorochemical as vehicles.20,32−35 
Intratracheal instillation of corticosteroids with a 
suitable vehicle therefore represents a promising 
method of local corticosteroid use for promoting 
drug distribution in the alveolar space.
Budesonide is a corticosteroid with a well-known 
local anti-inflammatory effect, and a terminal 
elimination half-life of approximately 2.3 hours in 
preschool children.36,37 Furthermore, budesonide in-
halation suspension is the first formulation designed 
to deliver budesonide by way of nebulization in in-
fants and children under 8 years of age with per-
sistent asthma.37 It has been commonly and safely 
used to control moderate-to-severe asthma in chil-
dren, and potent suppression of the local airway in-
flammation can be achieved with limited systemic 
exposure.36,37 Investigators have also demonstrated 
that significant decreases in inflammatory cells, pro-
teins, and cytokines in lung lavage could be achieved 
in children and animals following intratracheal 
budesonide administration.33,36 Thus intratracheal 
instillation is theoretically a suitable means of in-
troducing budesonide into the alveolar space for 
the purpose of decreasing the local inflammatory 
process in ventilated premature lungs.38
Exogenous surfactant has the ability to decrease 
alveolar surface tension. Animal studies have shown 
that lung surfactant can enhance the rate and ex-
tent of drug dissolution to the lung.39 The use of 
surfactant as a vehicle to deliver steroids to the 
lungs may be associated with better drug deposition 
in the airspace than the use of saline.40 Surfactant 
may therefore be an appropriate vehicle for deliv-
ering drugs into the pulmonary alveoli and increasing 
the airspace deposition of the drug.32,40 Further more, 
intratracheal instillation of exogenous surfactant 
Table 2   Lung injury scores of the experimental newborn piglets in control, surfactant (Surf), and Budesonide plus 
surfactant (Bude + Surf) groups*
Group Alveolar Interstitial Alveolar Interstitial Edema Atelectasis Necrosis Sum
 inflammation inflammation hemorrhage hemorrhage
Dependent site
 Control 4 (3−4) 4 (4) 3.5 (2−4) 4 (4) 4 (4) 4 (4) 4 (4)  27.5
 Surf 2 (1−4) 3 (2−4) 1 (1) 2.5 (2−3) 1.5 (1−2) 2.5 (2−3) 2.5 (2−3) 15† 
 Bude + Surf 2 (1−3) 3 (2−4) 1 (1) 2 (2−4) 1 (1) 1.5 (1−3) 2.5 (2−3) 14†
Non-dependent site
 Control 3.5 (3−4) 3.5 (3−4) 3 (3) 3.5 (3−4) 2 (2) 3.5 (3−4) 3.5 (3−4) 22.5
 Surf 2 (2) 3 (3) 1.5 (1−2) 2.5 (2−3) 1.5 (1−2) 2.5 (2−3) 2.5 (2−3) 15.5† 
 Bude + Surf 1 (1) 2.5 (2−3) 0.5 (0−1) 1.5 (0−2) 0.5 (0−1) 2 (0−3) 1.5 (1−2) 9.5†
*Data are expressed as median (range); †p < 0.05 versus control group for the same site. 
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to the lungs of premature infants with severe RDS 
has been used for more than 10 years, and the tech-
nique has been well practiced in most neonatal 
intensive care units.2 The combination of intratra-
cheally instilled exogenous surfactant and a cor-
ticosteroid in clinical practice will present few 
additional technical problems, compared with the 
use of surfactant alone, and it has been successfully 
used in premature infants.9 The present study also 
demonstrated that administration of the combination 
is no more complicated than that of the standard 
use of surfactant. However, the optimal dosage, ad-
ministration frequency, and administration intervals 
still need to be investigated.
Previous investigators found that budesonide 
had the potential to increase surfactant protein ex-
pression,41 and surface-active agents may improve 
the efficiency of budesonide.42 Surfactant and 
budesonide might thus demonstrate synergistic ef-
fects in intrapulmonary use. In the current study, 
we found that the use of budesonide in addition to 
surfactant did not improve oxygenation above that 
achieved with the use of surfactant alone over a 
4-hour period. This could be explained by the short 
duration of the experiments; a greater time period 
may be needed to increase the production of en-
dogenous surfactant in budesonide-instilled animals. 
However, there was a tendency towards less inflam-
matory cell infiltration, hemorrhage, and edema in 
the non-dependent lung tissue of budesonide-treated 
animals, compared with the animals treated with 
surfactant alone. Major amelioration of pulmonary 
inflammation without marked improvement in gas 
exchange following intratracheal instillation of a 
corticosteroid and surfactant have also been noted 
in some animal studies of paraquat-induced lung 
injury.33,43,44 Beneficial anti-inflammatory effects 
may also need a longer duration to be expressed. 
The present experiments only observed changes 
during the first 4 hours, and it was therefore only 
possible to compare the effects on the hyper-acute 
stage of lung injury. Longer observation periods 
are needed to elucidate the prolonged effects of 
the combined use of surfactant and budesonide in 
surfactant-deficient lungs.
The present pilot study was also limited by the 
small numbers of experimental animals in each 
group, which could have been responsible for the 
failure to detect significant differences between the 
treatment groups in terms of some parameters of gas 
exchange and lung injury score. Further studies with 
a larger sample size and longer observation times 
will be important for determining the potential ben-
efits of intratracheal instillation of budesonide in 
addition to surfactant in surfactant-deficient lungs.
In conclusion, the use of either exogenous sur-
factant alone or the combination of intratracheal 
instillation of surfactant and budesonide can improve 
the oxygenation and pulmonary histologic outcome 
in neonatal surfactant-depleted lungs over a 4-hour 
period. The additional use of budesonide did not 
disturb the surfactant function. Further investiga-
tions into the prolonged effects of the combination 
therapy will be necessary to elucidate the role of 
intratracheal administration of a corticosteroid com-
bined with surfactant in treating RDS in premature 
infants. We speculate that intratracheal adminis-
tration of a corticosteroid in combination with ex-
ogenous surfactant may be an effective method for 
alleviating local pulmonary inflammation with lim-
ited systemic influence in severe RDS.
Acknowledgments
This study was supported by grant V95A-068 from 
Taipei Veterans General Hospital, Taipei, Taiwan. 
The authors gratefully acknowledge the expert sta-
tistical assistance of Benjamin Ing-Tiau Kuo, (MD, 
PhD) at the Department of Medical Research and 
Education, Taipei Veterans General Hospital. We 
also gratefully acknowledge the technical assis-
tance provided by Miss Jui-Yu Lin at Taipei Veterans 
General Hospital.
References
1. Cools F, Henderson-Smart DJ, Offringa M, Askie LM. Elective 
high-frequency oscillatory ventilation versus conventional 
ventilation for acute pulmonary dysfunction in preterm 
infants. Cochrane Database Syst Rev 2009;3:CD000104.
2. Engle WA; American Academy of Pediatrics Committee on 
Fetus and Newborn. Surfactant-replacement therapy for res-
piratory distress in the preterm and term neonate. Pediatrics 
2008;121:419−32.
3. Crowley P. WITHDRAWN: Prophylactic corticosteroids for 
preterm birth. Cochrane Database Syst Rev 2007;3:
CD000065.
4. Shah V, Ohlsson A, Halliday HL, Dunn MS. Early administration 
of inhaled corticosteroids for preventing chronic lung disease 
in ventilated very low birth weight preterm neonates. 
Cochrane Database Syst Rev 2007;4:CD001969.
5. Sweet D, Bevilacqua G, Carnielli V, et al. European consen-
sus guidelines on the management of neonatal respiratory 
distress syndrome. J Perinat Med 2007;35:175−86.
6. Stevens TP, Blennow M, Myers EH, Soll R. Early surfactant 
administration with brief ventilation vs. selective surfactant 
and continued mechanical ventilation for preterm infants 
with or at risk for respiratory distress syndrome. Cochrane 
Database Syst Rev 2007;4:CD003063.
7. Crowther CA, Harding JE. Repeat doses of prenatal corti-
costeroids for women at risk of preterm birth for preventing 
neonatal respiratory disease. Cochrane Database Syst Rev 
2007;3:CD003935.
8. Teksam O, Kale G. The effects of surfactant and antenatal 
corticosteroid treatment on the pulmonary pathology of 
preterm infants with respiratory distress syndrome. Pathol 
Res Pract 2009;205:35−41.
226 C.F. Yang et al
9. Yeh TF, Lin HC, Chang CH, et al. Early intratracheal instilla-
tion of budesonide using surfactant as a vehicle to prevent 
chronic lung disease in preterm infants: a pilot study. 
Pediatrics 2008;121:e1310−8.
10. Collaborative Dexamethasone Trial Group. Dexamethasone 
therapy in neonatal chronic lung disease: an international 
placebo-controlled trial. Pediatrics 1991;88:421−7.
11. Yeh TF, Torre JA, Rastogi A, Anyebuno MA, Pildes RS. Early 
postnatal dexamethasone therapy in premature infants with 
severe respiratory distress syndrome: a double-blind, con-
trolled study. J Pediatr 1990;117:273−82.
12. Halliday HL, Ehrenkranz RA. Early postnatal (< 96 hours) 
corticosteroids for preventing chronic lung disease in pre-
term infants. Cochrane Database Syst Rev 2000;2:CD001146.
13. Vermont Oxford Network Steroid Study Group. Early postna-
tal dexamethasone therapy for the prevention of chronic 
lung disease. Pediatrics 2001;1083:741−8.
14. Buimer M, van Wassenaer AG, Kok JH. Postnatal administra-
tion of dexamethasone for weaning off the ventilator affects 
thyroid function. Neonatology 2008;94:164−9.
15. Shah SS, Ohlsson A, Halliday H, Shah VS. Inhaled versus sys-
temic corticosteroids for the treatment of chronic lung dis-
ease in ventilated very-low-birth-weight preterm infants. 
Cochrane Database Syst Rev 2007;4:CD002057.
16. Yeh TF, Lin YJ, Huang CC, et al. Early dexamethasone therapy 
in preterm infants: a follow-up study. Pediatrics 1998;101:E7.
17. Gross SJ, Anbar RD, Mettelman BB. Follow-up at 15 years of 
preterm infants from a controlled trial of moderately early 
dexamethasone for the prevention of chronic lung disease. 
Pediatrics 2005;115:681−7.
18. Shinwell ES, Karplus M, Reich D, et al. Early postnatal dex-
amethasone treatment and increased incidence of cerebral 
palsy. Arch Dis Child Fetal Neonatal Ed 2000;83:F177−81.
19. Jeng MJ, Soong WJ, Lee YS. Effective lavage volume of diluted 
surfactant improves the outcome of meconium aspiration 
syndrome in newborn piglets. Pediatr Res 2009;66:107−12.
20. Jeng MJ, Lee YS, Soong WJ. Effects of perfluorochemicals 
for intrapulmonary vancomycin administration and partial 
liquid ventilation in an animal model of meconium-injured 
lungs. Acta Paediatr Taiwan 2007;48:309−16.
21. Jeng MJ, Soong WJ, Lee YS, et al. Effects of therapeutic 
broncho-alveolar lavage and partial liquid ventilation on 
meconium-aspirated newborn piglets. Critical Care Medicine 
2006;34:1099−105.
22. Lachmann B, Roberston B, Petro W, et al. Experimental 
respiratory distress induced by removal of alveolar sur-
factant with bronchial lavage. Bull Eur Physiopath Respir 
1976;12:186−7.
23. Jeng MJ, Kou YR, Sheu CC, Hwang B. Effects of partial liquid 
ventilation with FC-77 on acute lung injury in newborn pig-
lets. Pediatr Pulmonol 2002;33:12−21.
24. Jeng MJ, Yang SS, Wolfson MR, Shaffer TH. Perfluorochemical 
(PFC) combinations for acute lung injury: an in vitro and in 
vivo study in juvenile rabbits. Pediatr Res 2003;53:81−8.
25. Rotta AT, Steinhorn DM. Partial liquid ventilation reduces 
pulmonary neutrophil accumulation in an experimental 
model of systemic endotoxemia and acute lung injury. Crit 
Care Med 1998;26:1707−15.
26. Jeng MJ, Kou YR, Sheu CC, Hwang B. Effects of exogenous 
surfactant supplementation and partial liquid ventilation 
on acute lung injury induced by wood smoke inhalation in 
newborn piglets. Crit Care Med 2003;31:1166−74.
27. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early 
(7−14 days) postnatal corticosteroids for preventing chronic 
lung disease in preterm infants. Cochrane Database Syst 
Rev 2003;1:CD001144.
28. Halliday HL, Ehrenkranz RA, Doyle LW. Late (> 7 days) post-
natal corticosteroids for chronic lung disease in preterm 
infants. Cochrane Database Syst Rev 2009;1:CD001145.
29. Halliday HL, Ehrenkranz RA, Doyle LW. Early (< 8 days) post-
natal corticosteroids for preventing chronic lung disease 
in preterm infants. Cochrane Database Syst Rev 2009;
1:CD001146.
30. Romagnoli C, Zecca E, Luciano R, Torrioli G, Tortorolo G. 
A three year follow-up of preterm infants after moderately 
early treatment with dexamethasone. Arch Dis Child Fetal 
Neonatal Ed 2002;87:F55−8.
31. O’Callaghan C, Hardy J, Stammers J, Stephenson TJ, Hull D. 
Evaluation of techniques for delivery of steroids to lungs of 
neonates using a rabbit model. Arch Dis Child 1992;67:20−4.
32. Fajardo C, Levin D, Garcia M, Adrams D, Adamson I. Surfactant 
versus saline as a vehicle for corticosteroid delivery to the 
lungs of ventilated rabbits. Pediatr Res 1998;43:542−7.
33. Chen CM, Fang CL, Chang CH. Surfactant and corticosteroid 
effects on lung function in a rat model of acute lung injury. 
Crit Care Med 2001;29:2169−75.
34. Cullen AB, Cox CA, Hipp SJ, Wolfson MR, Shaffer TH. Intra-
tracheal delivery strategy of gentamicin with partial liquid 
ventilation. Respir Med 1999;93:770−8.
35. Mokra D, Mokry J, Drgova A, Petraskova M, Bulikova J, 
Calkovska A. Intratracheally administered corticosteroids 
improve lung function in meconium-instilled rabbits. J Physiol 
Pharmacol 2007;58:389−98.
36. Hvizdos KM, Jarvis B. Budesonide inhalation suspension: 
a review of its use in infants, children and adults with inflam-
matory respiratory disorders. Drugs 2000;60:1141−78.
37. Szefler SJ. Pharmacodynamics and pharmacokinetics of 
budesonide: a new nebulized corticosteroid. J Allergy Clin 
Immunol 1999;104:175−83.
38. Arnon S. Grigg J, Nikander K, Silverman M. Delivery of 
micronized budesonide suspension by metered dose inhaler 
and jet nebulizer into a neonatal ventilator circuit. Pediatr 
Pulmonol 1992;13:172−5.
39. Plam S, Wiedmann TS. Note: dissolution of aerosol particles 
of budesonide in Survanta TM, a model lung surfactant. 
J Pharmaceutical Sci 2001;90:98−104.
40. Kharasch VS, Sweeney TD, Fredberg J, et al. Pulmonary sur-
factant as a vehicle for intratracheal delivery of technetium 
sulfur colloid and pentamidine in hamster lungs. Am Rev 
Respir Dis 1991;144:909−13.
41. Yu ZW, Zhang JH. Effect of inhaled budesonide on surfactant 
protein expression in asthmatic mice. Allergy Asthma Proc 
2008;29:486−92.
42. Bouwman AM, Heijstra MP, Schaefer NC, Duiverman EJ, 
Lesouëf PN, Devadason SG. Improved efficiency of budeso-
nide nebulization using surface-active agents. Drug Deliv 
2006;13:357−63.
43. Chen CM, Wang LF, Su B, Hsu HH. Methylprednisolone effects 
on oxygenation and histology in a rat model of acute lung 
injury. Pulm Pharmacol Ther 2003;16:215−20.
44. Chen CM, Su B, Hsu CC, Wang LF. Methylprednisolone does not 
enhance the surfactant effects on oxygenation and histology 
in paraquat-induced rat lung injury. Intensive Care Med 
2002;28:1138−44.
